From prototype to patient: why medical device developers need more than testing

Jessi Done, Sr. Director of Microbiology & Sterilization, Medical Device Services

A smarter path to medical device safety with Eurofins

Early in medical device development, innovation often takes center stage—new materials, mechanisms, and clinical applications. But innovation alone doesn’t bring a device to market. Safety, usability, and regulatory alignment ultimately determine success. Increasingly, manufacturers are turning to partners like Eurofins not just for testing, but for integrated, strategic support across the development lifecycle.

Rethinking when biological evaluation begins

Biological testing is often treated as a late stage requirement, but delaying it can lead to failures, redesigns, and regulatory setbacks. Aligning with ISO 10993 early enables creation of a Biological Evaluation Plan (BEP) tailored to device materials,contact duration, and clinical use. Early toxicological input helps teams make informed design and material decisions before they become costly to change—shifting biocompatibility from a compliance task to a design driver.

Building a complete biological profile

A device’s biological safety profile must be developed systematically. Foundational tests—cytotoxicity, sensitization, and irritation—establish baseline compatibility. Devices with prolonged or invasive contact require deeper evaluation, including systemic toxicity, genotoxicity, and pyrogenicity. Blood contacting devices undergo hemocompatibility testing to assess coagulation and immune interactions. Implantable devices add in vivo studies to evaluate long term tissue response. Together, these assessments create a comprehensive understanding of biological risk rather than isolated test results.

Microbiology: ensuring clean, controlled, and sterile products

For sterile or reusable devices, microbiological control is essential. Key evaluations include bioburden quantification, sterility testing, bacterial endotoxin testing, and environmental monitoring of manufacturing spaces. These studies support both initial approval and ongoing quality management.

Reprocessing: safety across reuse cycles

Reusable devices must remain safe after repeated cleaning and sterilization. Reprocessing validation confirms that devices can be effectively cleaned, disinfected or sterilized, dried, and maintained without functional or material degradation. Studies typically include simulated use, worst case contamination, cleaning efficacy, sterilization validation, and post cycle integrity testing. Regulators expect robust evidence that devices remain safe throughout their intended lifespan.

Usability as a core safety requirement

Even a biologically and mechanically sound device can pose risks if users cannot operate it correctly. Human factors engineering identifies use related risks, validates critical tasks, and ensures devices can be used safely in real world conditions. Regulators increasingly require this evidence, recognizing that usability is inseparable from overall safety.

EO sterilization: a critical enabler for sensitive devices

Ethylene oxide (EO) sterilization remains essential for many heat and moisture sensitive devices. Eurofins supports EO sterilization through development scale chambers and expert guided cycle development, validation to ISO 11135, pilot scale processing, and requalification support. Addressing sterilization early reduces risk and prevents costly redesigns tied to material compatibility, packaging, or regulatory strategy.

Extending safety beyond the device As commercialization nears, packaging, distribution, and aging studies become critical. Packaging must maintain sterility and integrity through transport and storage. Distribution testing simulates real world stresses, while aging studies establish shelf life. Each element represents a potential failure point if not addressed holistically.

The regulatory lens

Successful submissions—whether 510(k), De Novo, or PMA—depend on aligning testing strategies with regulatory expectations and sequencing studies appropriately. Early engagement with regulators helps clarify requirements and reduce uncertainty.

From service provider to strategic partner

Fragmented testing and consulting approaches introduce inefficiency and risk. Integrated partners like Eurofins provide coordinated expertise across toxicology, microbiology, human factors, packaging, sterilization, and regulatory strategy. This model improves study design, accelerates issue resolution, and enhances the overall development experience. Ultimately, success is defined not by passing tests, but by delivering safe, reliable devices to patients. For more information, visit: Eurofins.com/medical-device